

reimbursed for travel (including per diem in lieu of subsistence) and are reimbursed secretarial and correspondence expenses. Full-time Federal employees are reimbursed for travel expenses only.

Security Background Check: The selected nominee will undergo a thorough security background check. Security paperwork may take the nominee several weeks to complete. Nominees will also be required to complete a financial disclosure statement to avoid conflicts of interest.

Dated at Rockville, Maryland this 23 of October 2026.

For the U.S. Nuclear Regulatory Commission.

Tomas E. Herrera,

Deputy Secretary of the Commission.

[FR Doc. 2026-21881 Filed 10-26-26; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

[NRC-2026-0001]

Sunshine Act Meetings

TIME AND DATE: Weeks of October 26 and November 2, 9, 16, 23, 30, 2026. The schedule for Commission meetings is subject to change on short notice. The NRC Commission Meeting Schedule can be found on the internet at: <https://www.nrc.gov/public-involve/public-meetings/schedule.html>.

PLACE: The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings or need this meeting notice or the transcript or other information from the public meetings in another format (e.g., braille, large print), please contact the Reasonable Accommodations Resource by email at ReasonableAccommodations.Resource@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

STATUS: Public.

Members of the public may request to receive the information in these notices electronically. If you would like to be added to the distribution, please contact the Nuclear Regulatory Commission, Office of the Secretary, Washington, DC 20555, at 301-415-1969, or by email at Betty.Thweatt@nrc.gov or Samantha.Miklaszewski@nrc.gov.

MATTERS TO BE CONSIDERED:

Week of October 26, 2026

There are no meetings scheduled for the week of October 26, 2026.

Week of November 2, 2026—Tentative

There are no meetings scheduled for the week of November 2, 2026.

Week of November 9, 2026—Tentative

There are no meetings scheduled for the week of November 9, 2026.

Week of November 16, 2026—Tentative

There are no meetings scheduled for the week of November 16, 2026.

Week of November 23, 2026—Tentative

There are no meetings scheduled for the week of November 23, 2026.

Week of November 30, 2026—Tentative

There are no meetings scheduled for the week of November 30, 2026.

CONTACT PERSON FOR MORE INFORMATION:

For more information or to verify the status of meetings, contact Wesley Held at 301-287-3591 or via email at Wesley.Held@nrc.gov.

The NRC is holding the meetings under the authority of the Government in the Sunshine Act, 5 U.S.C. 552b.

Dated: October 23, 2026.

For the Nuclear Regulatory Commission.

Wesley W. Held,

Policy Coordinator, Office of the Secretary.

[FR Doc. 2026-21878 Filed 10-23-26; 11:15 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on the Medical Uses of Isotopes: Call for Nominations

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Call for nominations.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is soliciting nominations for the position of an Interventional Radiologist on the Advisory Committee on the Medical Uses of Isotopes (ACMUI). Nominees should currently be practicing as an Interventional Radiologist.

DATES: Nominations are due on or before December 28, 2026.

Nomination Process: Submit an electronic copy of resume or curriculum vitae, along with a cover letter, to Ms. Sarah Hoenig, Sarah.Hoenig@nrc.gov. The cover letter should describe the nominee's current duties and responsibilities and express the nominee's interest in the position. Please ensure that the resume or curriculum vitae includes the following information, if applicable: education; certification(s); professional association and committee membership activities;

duties and responsibilities in current and previous clinical, research, and/or academic position(s).

FOR FURTHER INFORMATION CONTACT:

Sarah Hoenig, U.S. Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards; 301-415-3284; Sarah.Hoenig@nrc.gov.

SUPPLEMENTARY INFORMATION:

ACMUI members possess the medical and technical skills needed to address evolving issues. The current membership is comprised of the following professionals: (a) nuclear medicine physician; (b) nuclear cardiologist; (c) two radiation oncologists; (d) diagnostic radiologist; (e) therapy medical physicist; (f) nuclear medicine physicist; (g) nuclear pharmacist; (h) radiation safety officer; (i) patients' rights advocate; (j) Food and Drug Administration representative; (k) Agreement State representative; and (l) interventional radiologist (vacant). For additional information about membership on the ACMUI, visit the ACMUI Membership web page, <http://www.nrc.gov/about-nrc/regulatory/advisory/acmui/membership.html>.

The ACMUI Interventional Radiologist provides advice on issues associated with the regulation of interventional radiology applications of byproduct material. This advice includes providing input on NRC proposed rules and guidance, providing recommendations on the training and experience requirements for Authorized Interventional Radiologists, identifying medical events associated with these uses, evaluating non-routine uses of byproduct material, bringing key issues in the interventional radiology community to the attention of NRC staff, radiation safety and NRC medical-use policy. This individual is appointed based on his or her educational background, certification(s), work experience, involvement and/or leadership in professional society activities, and other information obtained in letters or during the selection process.

Nominees must be U.S. citizens and be able to devote approximately 160 hours per year to ACMUI business. Members are expected to attend semi-annual full-day virtual meetings and to participate in other shorter teleconferences or virtual meetings, as needed. ACMUI members who present during the annual ACMUI Commission Briefing Meeting, may need to travel to attend these meetings in-person at NRC HQs in Rockville, MD. Committee members currently serve a four-year term and may be considered for reappointment to an additional term.

Members who are not Federal employees at the time of their appointment are compensated for their service. In addition, members are reimbursed for travel (including per diem in lieu of subsistence) and are reimbursed secretarial and correspondence expenses. Full-time Federal employees are reimbursed for travel expenses only.

Security Background Check: The selected nominee will undergo a thorough security background check. Security paperwork may take the nominee several weeks to complete.

Nominees will also be required to complete a financial disclosure statement to avoid conflicts of interest.

Dated at Rockville, Maryland, this 23 of October, 2026.

For the U.S. Nuclear Regulatory Commission.

Tomas E. Herrera,

Deputy Secretary of the Commission.

[FR Doc. 2026-21883 Filed 10-26-26; 8:45 am]

BILLING CODE 7590-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-106723; File No. 600-47]

Cboe Clear U.S., LLC; Order Granting an Application, as Amended, for Temporary Registration as a Clearing Agency Under Section 17A of the Securities Exchange Act of 1934

October 22, 2026.

I. Introduction

On June 30, 2026, Cboe Clear U.S., LLC (“CCUS”) filed with the Securities and Exchange Commission (“Commission”) an application on Form CA-1 under Section 17A of the Securities Exchange Act of 1934 (“Exchange Act”) ¹ seeking to register as a clearing agency to provide central counterparty (“CCP”) services for binary options that are securities.² In its application, CCUS requests temporary

registration as a clearing agency under Section 17A(b) of the Exchange Act and pursuant to 17 CFR 240.17ab2-1 (“Rule 17Ab2-1”).³ Notice of the application (“Notice”) was published for comment in the **Federal Register** on July 24, 2026.⁴ CCUS amended its application on July 7 and 17, August 18, September 4, and October 1,⁵ 2026 (as amended, “Application”).⁶

The Commission received one comment letter, as well as a response from CCUS.⁷ The comment letter supports approval of CCUS’s request for temporary registration as a “stopgap,” as to permanent registration, it raises concerns as to the risk of vertically integrated solutions and requests that the Commission consider the capital costs and risks of a more fragmented clearing structure.⁸ The comment letter received, and CCUS’s response thereto,⁹ are discussed in Parts III and IV.

This order grants CCUS’s request for temporary registration as a clearing agency with an exemption from certain requirements as to which the Commission is directed to make a determination under Sections 17A(b)(3)(B) and (F) for a period of 18 months from the date of this order, for the reasons set forth in Parts III and IV below.

³ See 17 CFR 240.17ab2-1(c).

⁴ Release No. 34-105960 (July 21, 2026), 90 FR 46817 (July 24, 2026) (“Notice”).

⁵ On August 18 and September 4, 2026, CCUS amended its application to update certain exhibits for which confidential treatment has been requested. On October 1, 2026, CCUS amended its application as follows: adding as Exhibit E-6 its Certificate of Good Standing; adding as Exhibit J-2 a copy of CCUS’s public disclosures under the CPMI-IOSCO *Principles for Financial Market Infrastructures*; and amending Exhibits A, E-2, E-3, J, L, O, and S, as further described in this order. In a separate release, the Commission has issued by delegated authority a notice of the October 1, 2026 amendments to the Application. Release No. 34-106610 (Oct. 6, 2026), 91 FR 64709 (Oct. 9, 2026). The Commission will consider any comments received regarding the October 1, 2026 amendment prior to taking any action on the Application with respect to permanent registration. See 17 CFR 240.17ab2-1(c) (providing that, not later than nine months from the date of any temporary registration is made effective, the Commission will grant registration or institute proceedings in accordance with Section 19 of the Exchange Act).

⁶ Non-confidential aspects of the Application and the exhibits thereto cited in this order, are available on the Commission’s website at: <https://www.sec.gov/rules-regulations/commission-orders-notices/other-commission-orders-notices-information/ccus-form-ca-1>. References to the Application throughout this order refer to the Application as most recently amended on October 1, 2026.

⁷ The public comment file for the Application is available on the Commission’s website at: <https://www.sec.gov/rules-regulations/public-comments/600-47>.

⁸ Letter from Joanna Mallers, Secretary, PTG, dated Sept. 8, 2026 (“PTG”).

⁹ Letter from Dale Michaels, President, Cboe Clear U.S., LLC, dated Sept. 25, 2026 (“CCUS Response”).

II. Statutory Standard for Registration as a Clearing Agency

Clearing agencies are broadly defined under the Exchange Act and undertake a variety of functions,¹⁰ including providing the services of a CCP.¹¹ Pursuant to Section 17A of the Exchange Act and Rule 17Ab2-1 thereunder, an entity that meets the definition of a clearing agency must register with the Commission.¹² Section 17A(b)(1) also states that, upon the Commission’s motion or upon a clearing agency’s application, the Commission may conditionally or unconditionally exempt a clearing agency from any provisions of Section 17A or the rules or regulations thereunder if the Commission finds that such exemption is consistent with the public interest, the protection of investors, and the purposes of Section 17A, including the prompt and accurate clearance and settlement of securities transactions and the safeguarding of securities and funds.¹³

In addition to the requirements set forth in Rule 17Ab2-1, Section 19(a)(1) of the Exchange Act establishes the standard for Commission review of an application for registration as a clearing agency. Pursuant thereto, the Commission shall grant registration of a clearing agency if it finds that the requirements of the Exchange Act and the rules and regulations thereunder with respect to the applicant are satisfied.¹⁴ The Commission shall deny such registration if it does not make such finding.¹⁵

The requirements of the Exchange Act applicable to clearing agencies are set forth in Section 17A and the rules and regulations thereunder.¹⁶ Accordingly,

¹⁰ 15 U.S.C. 78c(a)(23)(A) (providing the definition of “clearing agency”); see also Release No. 34-78961 (Sept. 28, 2016), 81 FR 70786, 70897 (Oct. 13, 2016) (“CCA Standards Adopting Release”) (stating that clearing agencies are broadly defined in the Exchange Act and undertake a variety of functions).

¹¹ See 17 CFR 240.17ad-22(a)(2) (defining “central counterparty” as a clearing agency that interposes itself between counterparties to securities transactions, acting functionally as the buyer to every seller and the seller to every buyer).

¹² 15 U.S.C. 78q-1(b); 17 CFR 240.17ab2-1 (“Rule 17Ab2-1”).

¹³ 15 U.S.C. 78q-1(b)(1).

¹⁴ 15 U.S.C. 78q-1; 15 U.S.C. 78s(a)(1).

¹⁵ 15 U.S.C. 78s(a)(1).

¹⁶ Rules for registered clearing agencies include recordkeeping requirements, 17 CFR 240.17a-1; the filing process for proposed rule changes, 17 CFR 240.19b-4; rules addressing operations and risk management, governance and conflicts of interest, and plans for recovery and wind-down at, respectively, 17 CFR 240.17ad-22 (“Rule 17Ad-22”), 240.17ad-25 (“Rule 17Ad-25”), and 240.17ad-26 (“Rule 17Ad-26”); and the requirements set forth in Regulation Systems Compliance and Integrity, 17 CFR 242.1000 *et seq.*